Anaphylaxis following a skin test with progesterone: A case report
Main Article Content
Keywords
anaphylaxis, omalizumab, progestogen hypersensitivity, urticaria
Abstract
Progestogen hypersensitivity is a broad spectrum of disorders that may present with cutaneous manifestations such as urticaria and eczema-like lesions, as well as systemic symptoms including anaphylaxis. Anaphylaxis due to progestogen hypersensitivity is very rare but should be considered in cases of recurrent anaphylaxis, particularly in young female patients. The timing of symptoms is the leading hint, as endogenous progesterone-induced reactions typically occur during the luteal phase of the menstrual cycle. Exogenous progesterone exposure, such as through oral contraceptives or assisted reproductive technologies (e.g., in vitro fertilization), has also been reported to trigger similar reactions. Therapeutic options include systemic corticosteroids, antihistamine tablets to control symptoms, and antihormone agents aiming the ovulation suppression. In refractory patients who are unresponsive to medical therapy, surgical options such as oophorectomy may be considered. In this report, a case of progesterone-associated anaphylaxis, triggered by an intradermal progesterone test, is presented, and a successful symptom control was achieved through the high-dose omalizumab treatment. As an alternative treatment option, omalizumab can be safely used in cases of progestogen hypersensitivity, especially in young female patients planning pregnancy.
References
2 Snyde JL, Krishnaswamy G. Autoimmune progesterone dermatitis and its manifestation as anaphylaxis: A case report and literature review. Ann Allergy Asthma Immunol. 2003;90(5):469–77; quiz 477, 571. 10.1016/S1081-1206(10)61838-8
3 Buchheit KM, Bernstein JA. Progestogen hypersensitivity: Heterogeneous manifestations with a common trigger. J Allergy Clin Immunol Pract. 2017;5(3):566–74. 10.1016/j.jaip.2017.01.019
4 Aghazadeh N, Chattha AJ, Hartz MF, Davis DMR. Autoimmune progesterone dermatitis in the adolescent population. Pediatr Dermatol. 2021;38(2):380–4. 10.1111/pde.14423
5 Xu G, Yuson R, Rafferty M, Thai TL, Limaye S. Progestogen hypersensitivity: Successful use of progesterone desensitisation and omalizumab to facilitate in vitro fertilisation. Intern Med J. 2024;54(10):1749–52. 10.1111/imj.16517
6 Varghese A, Paul T, Kim H, Van Uum S, Vadas P, Azzola A. Effect of omalizumab for autoimmune progesterone dermatitis refractory to bilateral oophorectomy: A case report. Allergy Asthma Clin Immunol. 2021;17(1):58. 10.1186/s13223-021-00561-2
7 Dhaliwal G, Batra J, Ankireddypalli AR, Gorle S, Kanugula AK, Kaur J. Progesterone hypersensitivity induced by exogenous progesterone exposure. Cureus. 2023;15(9):e44776. 10.7759/cureus.44776
8 Ghosh D, Bernstein JA. Development of a progesterone-specific IgE assay for diagnosing patients with suspected progestogen hypersensitivity. Ann Allergy Asthma Immunol. 2019;122(6):616–22. 10.1016/j.anai.2019.03.032
9 Ljubojevic Hadzavdic S, Kulišić SM, Grgec DL, Poljanac A, Ilić B. Autoimmune progesterone dermatitis diagnosed by lymphocyte transformation test and progesterone provocation test. Acta Dermatovenerol Croat. 2018;26(3):276–7.
10 Oskay T, Kutluay L, Kaptanoğlu A, Karabacak O. Autoimmune progesterone dermatitis. Eur J Dermatol. 2002;12(6):589–91.
11 Le K, Wood G. A case of autoimmune progesterone dermatitis diagnosed by progesterone pessary. Australas J Dermatol. 2011;52(2):139–41. 10.1111/j.1440-0960.2011.00753.x
12 Nemeth H, Kovács E, Gödény S, Simics E, Pfliegler G. Autoimmune progesterone dermatitis diagnosed by intravaginal progesterone provocation in a hysterectomised woman. Gynecol Endocrinol. 2009;25(6):410–2. 10.1080/09513590902770164
13 Medeiros S, Rodrigues-Alves R, Costa M, Afonso A, Rodrigues A, Cardoso J. Autoimmune progesterone dermatitis: Treatment with oophorectomy. Clin Exp Dermatol. 2010;35(3):e12–3. 10.1111/j.1365-2230.2009.03217.x
14 Aksoy FÇ, Evans SE, Karaduman A. Otoimmün progesteron dermatiti: Olgu sunumu ve literatürün g özden geçirilmesi. Arch Turk Dermatol Venerol Turkderm. 2009;43(3):122–5.
15 Kasperska-Zajac A, Brzoza Z, Rogala B. Sex hormones and urticaria. J Dermatol Sci. 2008;52(2):79–86. 10.1016/j.jdermsci.2008.04.002
16 Li RC, Buchheit KM, Bernstein JA. Progestogen hypersensitivity. Curr Allergy Asthma Rep. 2018;18(1):1. 10.1007/s11882-018-0758-x
17 Foer D, Buchheit KM. Progestogen hypersensitivity: An evidence-based approach to diagnosis and management in clinical practice. Immunol Allergy Clin North Am. 2017;37(4):773–84. 10.1016/j.iac.2017.07.006
18 Stranahan D, Rausch D, Deng A, Gaspari A. The role of intradermal skin testing and patch testing in the diagnosis of autoimmune progesterone dermatitis. Dermatitis. 2006;17(1):39–42. 10.2310/6620.2006.05045
19 Foer D, Tran LK, Wickner P, Castells M, Marquis KA, Buchheit KM. Challenges in skin testing for progestogen hypersensitivity. Ann Allergy Asthma Immunol. 2021;126(1):100–2. 10.1016/j.anai.2020.09.002
20 Toms-Whittle LM, John LH, Griffiths DJ, Buckley DA. Autoimmune progesterone dermatitis: A diagnosis easily missed. Clin Exp Dermatol. 2011;36(4):378–80. 10.1111/j.1365-2230.2010.03979.x
21 Foer D, Buchheit KM, Gargiulo AR, Lynch DM, Castells M, Wickner PG. Progestogen hypersensitivity in 24 cases: Diagnosis, management, and proposed renaming and classification. J Allergy Clin Immunol Pract. 2016;4(4):723–9. 10.1016/j.jaip.2016.03.003
22 Pongdee T, Li JT. Omalizumab safety concerns. J Allergy Clin Immunol. 2025;155(1):31–5. 10.1016/j.jaci.2024.11.005
23 Patruno C, Guarneri F, Nettis E, Bonzano L, Filippi F, Ribero S, et al. Safety of omalizumab in chronic urticaria during pregnancy: A real-life study. Clin Exp Dermatol. 2024;49(4):344–7. 10.1093/ced/llad386
24 Heffler E, Fichera S, Nicolosi G, Crimi N. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab. J Allergy Clin Immunol Pract. 2017;5(3):852–4. 10.1016/j.jaip.2017.01.003
25 Gadoury-Levesque V, Bernstein J. A case of refractory recurrent cyclical angioedema and urticaria successfully treated with multiple steps therapy. Annals Allergy Asthma Immunol. 2018;121(5):S85. 10.1016/j.anai.2018.09.276
26 Lavery WJ, Bernstein JA. Cyclical hypersensitivity, anaphylaxis, and related hormonal reaction. Ann Allergy Asthma Immunol. 2019;122(2):140–7. 10.1016/j.anai.2018.11.016
27 Prieto-Garcia A, Sloane DE, Gargiulo AR, Feldweg AM, Castells M. Autoimmune progesterone dermatitis: Clinical presentation and management with progesterone desensitization for successful in vitro fertilization. Fertil Steril. 2011;95(3):1121 e9–13. 10.1016/j.fertnstert.2010.10.038